Autonomic dysfunction is a hallmark feature of Progressive Supranuclear Palsy (PSP), contributing significantly to morbidity, reduced quality of life, and mortality. Unlike Parkinson's disease where autonomic symptoms often develop later, PSP patients frequently present with early and severe autonomic impairment, reflecting the brainstem and subcortical pathology that characterizes the disease[1]. The autonomic nervous system dysfunction in PSP results from neurodegeneration in key structures including the dorsal vagal nucleus, nucleus tractus solitarius, rostral ventromedial medulla, and hypothalamic nuclei[2].
This page comprehensively covers the pathophysiology, clinical manifestations, diagnosis, and management of autonomic dysfunction in PSP, with particular attention to evidence from recent cohort studies and clinical trials.
The autonomic manifestations in PSP stem from the distinctive pattern of tau pathology that affects brainstem nuclei involved in autonomic regulation:
Orthostatic hypotension (OH) affects 30-50% of PSP patients, significantly higher than previously recognized. The pathophysiology involves:
Supine hypertension (SH) coexists with orthostatic hypotension in approximately 60% of affected patients, resulting from compensatory mechanisms and baroreflex desensitization [4]. This creates a therapeutic challenge, as treatment of OH may worsen SH.
Reduced heart rate variability (HRV) is present in PSP even in early stages, reflecting parasympathetic dysfunction. Studies show:
Urinary symptoms in PSP are among the most disabling autonomic features:
| Symptom | Prevalence | Pathophysiology |
|---|---|---|
| Urinary urgency | 70-80% | Detrusor overactivity from frontal lobe inhibition loss |
| Nocturia | 65-75% | Combined detrusor dysfunction + sleep fragmentation |
| Urinary retention | 20-30% | External sphincter bradykinesia |
| Incontinence | 15-25% | Combined urge and overflow mechanisms |
The " Hoover's sign" in urology—weak urinary stream with difficulty initiating—reflects the bradykinetic external sphincter [6].
Excessive sweating, particularly on the face and scalp, affects up to 60% of PSP patients. This results from:
Paradoxically, some patients develop reduced sweating (anhidrosis), particularly in the lower extremities, due to postganglionic sympathetic dysfunction [8].
Gastrointestinal manifestations in PSP include:
The pathophysiology involves vagal nucleus degeneration and Lewy body-like tau inclusions in enteric neurons [9].
Autonomic pupillary abnormalities in PSP include:
Standardized autonomic testing includes:
Validated instruments for PSP autonomic assessment include:
| Medication | Dose | Mechanism | Evidence Level |
|---|---|---|---|
| Midodrine | 2.5-10mg TID | α1-agonist | Moderate |
| Fludrocortisone | 0.05-0.2mg QD | Mineralocorticoid | Moderate |
| Droxidopa | 100-600mg TID | NE prodrug | High (FDA approved) |
| Pyridostigmine | 30-60mg TID | AChE inhibitor | Low-moderate |
| Atomoxetine | 10-40mg BID | NRI | Moderate |
Important: Supine hypertension management includes evening salty snacks, head-of-bed elevation, and short-acting antihypertensives at bedtime [10].
Autonomic dysfunction in PSP carries significant prognostic value:
Active trials targeting autonomic dysfunction in PSP include:
Wenning GK, et al. Autonomic dysfunction in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1999. ↩︎
Jellinger KA. Neuropathology of progressive supranuclear palsy. Mov Disord. 2001. ↩︎
Kashihara K, et al. 123I-MIBG cardiac scintigraphy provides evidence of cardiac sympathetic denervation in PSP. Parkinsonism Relat Disord. 2006. ↩︎
Freeman R, et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and supine hypertension. Clin Auton Res. 2007. ↩︎
Asahina M, et al. Heart rate variability in progressive supranuclear palsy. J Neurol Sci. 2013. ↩︎
Kim HJ, et al. Urodynamic findings in progressive supranuclear palsy. J Urol. 2014. ↩︎
Coon EA, et al. Thermoregulatory dysfunction in progressive supranuclear palsy. Neurology. 2015. ↩︎
Low PA, et al. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983. ↩︎
Colosimo C, et al. Gastrointestinal involvement in progressive supranuclear palsy. Mov Disord. 2010. ↩︎
Gibbons CH, et al. The management of supine hypertension in autonomic failure. Clin Auton Res. 2012. ↩︎
Maule S, et al. Orthostatic hypotension and mortality in neurodegenerative disease. Clin Auton Res. 2016. ↩︎
Singer W, et al. Plasma neurofilament light chain predicts autonomic dysfunction in neurodegenerative disease. Neurology. 2020. ↩︎
Treglia G, et al. Cardiac MIBG scintigraphy in differential diagnosis between Parkinson disease and progressive supranuclear palsy. Clin Nucl Med. 2012. ↩︎